BIGG Rec Logo
BIGG Rec Logo
Guideline

WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update

Year of Publication
2016
Issuing Institution
Links
Pubmed,WHO IRIS

Recommendations

4 included recommendations

In patients with isoniazid-resistant, rifampicin-resistant TB or multidrug-resistant TB , a regimen with at least five effective TB medicines during the intensive phase is recommended, including pyrazinamide and four core second-line TB medicines – one chosen from Group A, one from Group B, and at least two from Group C. If the minimum number of effective TB medicines cannot be composed as given above, an agent from Group D2 and other agents from Group D3 may be added to bring the total to five.. Group A=levofloxacin, moxifloxacin, gatifloxacin; Group B=amikacin, capreomycin, kanamycin, (streptomycin); Group C= ethionamide (or prothionamide), cycloserine (or terizidone), linezolid, clofazimine; in children with nonsevere disease Group B medicines may be excluded. Group D2=bedaquiline, delamanid; Group D3=p-aminosalicylic acid, imipenem–cilastatin, meropenem, amoxicillin clavulanate, (thioacetazone). Bedaquiline is only recommended for adults; delamanid may also be used in patients aged 6–17 years.

Status
Retired

Recommended in favor

Conditional

Powered byEpistemonikos Foundation